 |
 |
|
|
Clinical Research Trials
Participation in research and clinical investigation is an important commitment of Hoag Neurosciences Institute in its mission to provide patients access to leading-edge management and treatment for neurological disorders.
Research Programs
Hoag’s sub-specialized team of neuroscientists are actively involved in research to discover new therapies, drugs and other medical advancements to better the lives of patients suffering from neurological conditions.
For information, please call the neuroscience clinical trials nursing staff at 949/764-8190.
Clinical Trials
Hoag Neurosciences Institute is currently accepting patients to participate in a number of clinical research trials. Please contact Laura Whitaker, RN at 949/764-8190 or email laura.whitaker@hoaghospital.org to learn more about each protocol and whether you may qualify. Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care.
Acute Ischemic Stroke
David Brown, MD Principal Investigator
Interventional Management of Stroke (IMS III) Trial compares the current approved therapy of IV rt-PA alone versus IV rt-PA plus intra-arterial rt-PA. Patients must present to the hospital within 3 hours from stroke onset and otherwise be eligible to receive the current IV rt-PA therapy. All study related procedures, medication, and follow up visits are at no cost to the patient.
PET Imaging for Lung, Head, and Neck Cancers
Michael Brant-Zawadzki, MD Principal Investigator
An investigational biomarker for PET/CT is being compared to the standard biomarker FDG in identifying earlier response to chemoradiation or radiation therapy in patients diagnosed with either lung, head, or neck cancer. Patients must be willing to have two PETs prior to the start of their therapy and again at 4-5 weeks after the beginning of their radiation or chemoradiation. All study related PET imaging, exams, and visits are at no cost and compensation is available.
Acute Repetitive Seizures
Richard Kim, MD Principal Investigator
An alternative to Diastat, this study is evaluating the safety and efficacy of an investigational medication for Acute Repetitive Seizures for patients 2 years old and up. Potential participants must have experienced ARS at least once in the last 6 months, with no status epilepticus in the last year. Compensation is available for time and travel, caregivers are trained on how to administer medication at home.
Glioblastoma (brain): Intralesional Adoptive Cellular Therapy of Glioblastoma
Click here for more information
|
|
|
|